Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$74.45 USD

74.45
2,643,262

+0.67 (0.91%)

Updated Aug 19, 2024 03:59 PM ET

After-Market: $74.43 -0.02 (-0.03%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.

    Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat

    Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.

      Sheraz Mian headshot

      Q2 Scorecard & Research Reports for Gilead, American Tower & Others

      Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), American Tower (AMT) and Chubb (CB).

        Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2

        Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.

          Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks

          Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.

            bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

            bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.

              Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

              Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.

                Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

                Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

                  Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

                  Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

                    Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View

                    Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.

                      5 Cheap PEG Stocks Suitable for GARP Investors

                      Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.

                        Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

                        During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.

                          Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2

                          Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.

                            Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

                            Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

                              Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

                              Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

                                Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

                                Is (GILD) Outperforming Other Medical Stocks This Year?

                                  Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

                                  Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

                                    AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

                                    AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

                                      Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

                                      ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

                                        Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

                                        Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

                                          Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

                                          Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

                                            Mark Vickery headshot

                                            Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM

                                            Facebook has posted a one-penny miss, but revenues also came in lower than expected.

                                              Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates

                                              Gilead (GILD) delivered earnings and revenue surprises of 23.23% and 9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                                                Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

                                                The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.

                                                  Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?

                                                  Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.